

Development of a novel RIPK1 inhibitor for autoimmune disease(BSC-1300)

BiSiChem



BiSiChem

IMMUNOLOGY	Candidate
Product Type	Small molecule
Indication	Autoimmune diseases (Psoriasis, RA, and UC)
Target	The receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
MoA(Mechanism of Action)	Inhibition of RIPK1 suppresses necroptosis and inflammation
Competitiveness	<p>First-in-Class / Best-in-Class:</p> <ul style="list-style-type: none"> - BSC-1300 is a highly potent necroptosis inhibitor targeting RIPK1 and improved systemic exposure than SAR443122. - Achieves highly selective RIPK1 kinase inhibition against off-target kinases. - Improves the Psoriasis and RA therapeutic efficacy compared to other clinical drugs.
Development Stage	Candidate
Route of Administration	Oral